


In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-13. (cancelled)

14. (currently amended) The A method of treating irritable bowel syndrome, which comprises administering to a patient in need thereof an effective amount of a compound having NMDA receptor antagonist activity according to claim 9 wherein the compound is a compound of formula (I) or a metabolite or isomer thereof



where:

R<sup>1</sup> and R<sup>2</sup> are independently phenyl or 4-fluorophenyl;

R<sup>3</sup> is hydrogen, C<sub>1-6</sub> alkyl or methoxycarbonyl;

R<sup>4</sup> is hydrogen or methyl;

as a free base or a pharmaceutically acceptable salt thereof.

15. (previously presented) The method according to claim 14 wherein the compound is remacemide or a pharmaceutically acceptable salt thereof.

16. (previously presented) The method according to claim 14 wherein the compound is 2,3-diphenyl-2-propylamine or a pharmaceutically acceptable salt thereof.

17. (currently amended) The A method according to claim 14 of treating irritable bowel syndrome, which comprises administering to a patient in need thereof an effective amount of a compound having NMDA receptor antagonist activity wherein the compound is (S)-1-phenyl-2-(2-pyridyl)ethanamine or a pharmaceutically acceptable salt thereof.

18. (currently amended) The A method according to claim 9 of treating irritable bowel syndrome, which comprises administering to a patient in need thereof an effective amount of a compound having NMDA receptor antagonist activity wherein the compound is memantine or a pharmaceutically acceptable salt thereof.

19. (currently amended) The A method according to claim 9 of treating irritable bowel syndrome, which comprises administering to a patient in need thereof an effective amount of a compound

having NMDA receptor antagonist activity wherein the compound is 2-amino-N-(1,2-diphenylethyl)acetamide, alpha-phenyl-1H-pyrazole-1-ethanamine, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine, or 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine or a pharmaceutically acceptable salt thereof.